BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/4/2018 1:15:45 PM | Browse: 1200 | Download: 1903
 |
Received |
|
2018-02-05 06:01 |
|
Peer-Review Started |
|
2018-02-05 06:28 |
|
To Make the First Decision |
|
2018-02-24 01:21 |
|
Return for Revision |
|
2018-02-26 03:37 |
|
Revised |
|
2018-02-26 07:33 |
|
Second Decision |
|
2018-03-06 09:43 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2018-03-06 16:59 |
|
Articles in Press |
|
2018-03-06 16:59 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2018-04-03 05:48 |
|
Publish the Manuscript Online |
|
2018-04-04 13:15 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Prospective Study |
| Article Title |
Hepatocellular carcinoma or interferon-based therapy history attenuates sofosbuvir/ribavirin for Japanese genotype 2 hepatitis C virus
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Masayoshi Yada, Masayuki Miyazaki, Kosuke Tanaka, Akihide Masumoto and Kenta Motomura |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Masayoshi Yada, MD, PhD, Doctor, Doctor, Department of Hepatology, Iizuka Hospital, 3-83 Yoshio-machi, Iizuka 820－8505, Fukuoka, Japan. myadah1@aih-net.com |
| Key Words |
Sofosbuvir; Ribavirin; Genotype 2; Hepatitis C virus; Interferon-based therapy; Hepatocellular carcinoma |
| Core Tip |
The real-world efficacy of sofosbuvir/ribavirin therapy for genotype 2 hepatitis C virus infection in Japan is high. Sofosbuvir/ribavirin therapy is safe and highly tolerated. History of hepatocellular carcinoma or interferon-based therapy independently reduces the efficacy of sofosbuvir/ribavirin therapy. Progressive liver fibrosis may attenuate the antiviral effect of sofosbuvir/ribavirin therapy. |
| Publish Date |
2018-04-04 13:15 |
| Citation |
Yada M, Miyazaki M, Tanaka K, Masumoto A, Motomura K. Hepatocellular carcinoma or interferon-based therapy history attenuates sofosbuvir/ribavirin for Japanese genotype 2 hepatitis C virus. World J Gastroenterol 2018; 24(13): 1478-1485 |
| URL |
http://www.wjgnet.com/1007-9327/full/v24/i13/1478.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v24.i13.1478 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
